Skip to main content

Table 3 Variables associated with SVR12 in univariate and multivariate analysis

From: Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort

 

n with SVR 12 / Total (%): Yes VS Reference

Univariate

Multivariate

OR (95% CI)

p-Value

OR (95% CI)

p-Value

Ribavirin containing regimen (reference: no RBV)

60/63 (95) VS 495/536 (92)

1.66 (0.5–8.61)

0.5936

  

Treatment duration 24 weeks (reference: 12 weeks)

62/69 (90) VS 493/530 (93)

0.67 (0.28–1.85)

0.4654

  

Cirrhosis (reference: no cirrhosis)

304/335 (91) VS 244/257 (95)

0.52 (0.25–1.06)

0.0734

1.07 (0.36–3.20)

1.0000

Conjugated bilirubin ≥5 μmol/L (reference: <  5 μmol/L)

163/182 (90) VS 141/148 (95)

0.43 (0.15–1.1)

0,0835

0.58 (0.19–1.67)

0.3701

TP ≤ 70% (reference: >  70%)

59/68 (87) VS 458/491 (93)

0.47 (0.21–1.18)

0.1103

0.41 (0.14–1.22)

0.1148

Hemoglobin ≤12 g/dL for women or ≤ 13 g/dL for men(reference: > 12 g/dL or > 13 g/dL)

63/72 (88) VS 480/514 (93)

0.5 (0.22–1.23)

0.1338

0.59 (0.22–1.71)

0.3620

Platelets < 100,000/mm3 (reference: ≥ 100,000/mm3)

108/121 (89) VS 429/458 (94)

0.56 (0.27–1.22)

0.1505

1.12 (0.39–3.38)

1.0000

Genotype 1b (reference: 1 not subtyped or 1a or 4)

280/297 (94) VS 275/302 (91)

1.62 (0.83–3.24)

0.1757

0.94 (0.39–2.26)

1.0000

Male (reference: Female)

303/322 (94) VS 252/277 (91)

1.18 (0.65–2.13)

0.6504

1.62 (0.68–3.94)

0.3192

Genotype 1a (reference: 1 not subtyped or 1b or 4)

127/141 (90) VS 428/458 (93)

0.64 (0.32–1.34)

0.2489

  

Neutrophil < 1500/mm3 (reference: ≥ 1500/mm3)

33/38 (87) VS 503/540 (93)

0.49 (0.17–1.69)

0.2641

  

Chronic hepatitis duration ≥15 years (reference: <  15 years)

308/337 (91) VS 236/251 (94)

0.68 (0.33–1.34)

0.2980

  

Albumin < 30 g/L (reference: ≥ 30 g/L)

16/19 (84) VS 479/519 (92)

0.45 (0.12–2.49)

0.3756

  

Age > 65 years (reference: ≤ 65 years)

209/223 (94) VS 346/376 (92)

1.29 (0.65–2.7)

0.5478

  

MELD ≥15 (reference: <  15)

31/35 (89) VS 454/491 (92)

0.63 (0.21–2.6)

0.5732

  

Genotype 4 (reference: 1a or 1b or 1 not subtyped)

121/132 (92) VS 434/467 (93)

0.84 (0.4–1.89)

0.7409

  

Viral load < 6 M at beginning of treatment (reference: ≥ 6 M)

502/542 (93) VS 42/44 (95)

0.6 (0.07–2.45)

0.7425

  

ALAT > 5 ULN (reference: ≤ 5ULN)

33/35 (94) VS 511/551 (93)

1.29 (0.31–11.5)

0.9999

  

ASAT > 5 ULN (reference: ≤ 5ULN)

34/37 (92) VS 508/547 (93)

0.87 (0.26–4.63)

0.9999

  

Decompensated cirrhosis (reference: no decompensated cirrhosis)

22/24 (92) VS 533/575 (93)

0.87 (0.2–7.86)

0.9999

  

Treatment experienced (reference: treatment naïve)

160/173 (92) VS 395/426 (93)

0.97 (0.48–2.07)

0.9999

  

Genotype 1 not subtyped (reference: 1a or 1b or 4)

27/29 (93) VS 528/570 (93)

1.07 (0.25–9.63)

0.9999

  

Previous treatment: PEG/RBV (reference: 1st generation PI/PEG/RBV or none)

365/394 (93) VS 190/205 (93)

0.99 (0.48–1.97)

0.9999

  
  1. SVR Sustain virological response, RBV Ribavirin, PEG Pegylated interferon, PI Protease inhibitor